To assess the efficacy of PDE inhibition and Gucy2C activation treatments, we employed the apomorphine rotations test, a valuable tool for the in vivo treatment efficacy in Parkinson's disease. The gene discussed is ALDH7A1; the disease is Parkinson disease.